Clinical trials: CIN1
High-risk HPV Infection and Biopsy-proven CIN1
An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101
Phase I, open-label, sequential-cohort, ascending multiple-dose study to evaluate the safety and tolerability of escalating doses of PDS0101 in female subjects with high-risk HPV infection and biopsy-proven CIN1.
- Trial name
- NCT02065973
- Testing
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PDS Biotechnology Corp.
Cervical Cancer, Precancerous Condition
Diindolylmethane in Treating Patients With Abnormal Cervical Cells
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of diindolylmethane, a substance found in cruciferous vegetables, may keep cervical intraepithelial neoplasia or cervical cancer from…
- Trial name
- NCT00462813
- Testing
- oral microencapsulated diindolylmethane, polymerase chain reaction, cervical Papanicolaou test
- Where
- 2 sites in United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- Barts and the London School of Medicine and Dentistry
Norovirus Infections
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
The purpose of this study is to determine a suitable dose of the human norovirus GII.4 challenge pool(CIN-1;031693) that induces illness in approximately 50% of susceptible subjects that would be useful for evaluation of vaccines…
- Trial name
- CIN-002 (NCT01435811)
- Testing
- Norovirus challenge pool (GII.4, CIN-1)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cervical Cancers, Vulvar Cancer
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
To evaluate the safety and immunogenicity of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years.
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, CIN1
- Trial name
- NCT03676101
- Testing
- 9-valent HPV Recombinant Vaccine
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Low-Grade Intraepithelial Neoplasia of Cervix
Evaluation of Oral EGCG Treatment for L-SIL Associated With HPV Infection
The study aims to evaluate the effectiveness of the synergy of oral Epigallocatechin Gallate as a treatment for Low-grade Cervical Lesions (L-SIL) associated with Human Papilloma Virus (HPV) infection.
- Trial name
- EGCG-HPV (NCT06314113)
- Testing
- Epigallocatechin Gallate
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo